THE PHARMACOKINETICS OF GADOLINIUM-DTPA IN THE PRESENCE OF CHRONIC RENAL-INSUFFICIENCY REQUIRING DIALYSIS

被引：11

作者：

KRAHE, T

GOTZ, R

LACKNER, K

HAUSTEIN, J

KLEMENZ, U

LANDWEHR, P

HEIDBREDER, E

SCHUHMANNGIAMPIERI, G

机构：

[1] UNIV WURZBURG,NEPHROL ABT,W-8700 WURZBURG,GERMANY

[2] UNIV WURZBURG,MED KLIN,W-8700 WURZBURG,GERMANY

[3] SCHERING AG,BERLIN,GERMANY

来源：

FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NEUEN BILDGEBENDEN VERFAHREN | 1992年 / 156卷 / 06期

关键词：

RENAL FAILURE; GADOLINIUM DTPA; PHARMACOKINETICS;

D O I：

10.1055/s-2008-1032936

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

MRT with gadolinium-DTPA (0.1 mmol/kg body weight) was performed in 10 patients with renal insufficiency requiring dialysis and the clearance of gadolinium-DTPA was studied. After 3 dialysis on 3 successive days more than 97 % of the initial concentration of gadolinium-DTPA had been eliminated. Average half-life was 1.87 hours. There were no side effects in any of the patients. Close laboratory observation of liver function showed no significant changes during the period of study. No contra-indication for the use of this contrast medium in patients with renal insufficiency requiring dialysis was found during this study.

引用

页码：523 / 526

页数：4

共 9 条

[1]

BAARS HG, 1984, Z UROL NEPHROL, V77, P473

[2] EXCRETION UROGRAPHY .I. FACTORS DETERMINING EXCRETION OF HYPAQUE [J].